LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$30.17 USD
-0.31 (-1.02%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $29.85 -0.32 (-1.06%) 5:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LENZ 30.17 -0.31(-1.02%)
Will LENZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LENZ
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
LENZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Other News for LENZ
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
Lenz Therapeutics price target raised by $9 at BofA, here's why
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
Lenz Therapeutics price target raised by $8 at H.C. Wainwright, here's why